Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms

Pranita D. Tamma, Alice J. Hsu

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and/or have low efficacy. However, several β-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.

Original languageEnglish (US)
Pages (from-to)251-260
Number of pages10
JournalJournal of the Pediatric Infectious Diseases Society
Issue number3
StatePublished - Jul 1 2019


  • Aztreonam-avibactam
  • Cefiderocol
  • Ceftazidime-avibactam
  • Ceftolozane-tazobactam
  • Imipenem-cilastatin-relebactam
  • Meropenem-vaborbactam

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases


Dive into the research topics of 'Defining the role of novel β-lactam agents that target carbapenem-resistant gram-negative organisms'. Together they form a unique fingerprint.

Cite this